Cognition Therapeutics Reveals Key Pathways in Alzheimer's and Parkinson's Diseases via Sigma-2 Receptor Modulators

On November 15, 2023, Cognition Therapeutics, Inc., a pioneering clinical-stage biopharmaceutical company with the identifier CGTX, disclosed compelling preclinical findings at the Society for Neuroscience's annual gathering. These findings highlight the significant role of sigma-2 (σ-2) receptor modulators in treating neurodegenerative diseases. The preclinical results, derived from in vivo studies, have opened new vistas in understanding Alzheimer's and Parkinson's diseases.

Exploring the Sigma-2 Receptor

The sigma-2 receptor is increasingly recognized as a consequential player in the fight against neurodegenerative diseases. CGTX's investigation into small molecule modulators, particularly CT1812, has uncovered ways they interact with the brain. This research is a substantial stride in realizing the potential mechanisms through which these compounds may offer therapeutic benefits for diseases such as Alzheimer's and Parkinson's.

Pioneering Treatments for Degenerative Diseases

CGTX stands at the forefront of developing groundbreaking treatments targeting age-related degenerative diseases. With its headquarters in Purchase, New York, the company is steadfast in its mission to combat disorders that impact the central nervous system and retina. As CGTX continues its rigorous research and development, the medical community eagerly anticipates further breakthroughs from their dedicated scientific efforts.

Alzheimer's, Parkinson's, biopharmaceutical